08
Sat, Oct
52 New Articles

BDK Advokati Advises Frontier Pharma and Baystone on Acquisition of Zdravlje Leskovac

BDK Advokati Advises Frontier Pharma and Baystone on Acquisition of Zdravlje Leskovac

Serbia
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

BDK Advokati has advised Frontier Pharma and the Baystone investment group on the acquisition of Zdravlje Leskovac, a Serbian pharmaceutical company owned by Actavis, which is itself a subsidiary of Israel's Teva. Karanovic & Partners advised the sellers on the deal, which is expected to close in March of 2021.

According to BDK Advokati, “Baystone and Frontier Pharma are expected to further invest in Zdravlje Leskovac production and bring additional products to the facility over time."

BDK Advokati’s team included Managing Partner Tijana Kojovic, Senior Partner Vladimir Dasic, Associates Jelena Zelenbaba and Bisera Andrijasevic, and Junior Associate Sanja Dedovic.

Karanovic & Partners' team included Senior Partner Dragan Karanovic, Partners Milos Jakovljevic, Bojan Vuckovic, and Goran Radosevic, and Senior Associate Sava Draca.

Our Latest Issue